Lucid Diagnostics (LUCD) Registration Filing summary

Company overview and business model

• Commercial-stage diagnostics company focused on noninvasive detection of esophageal precancer and cancer in GERD patients.

• Core products are EsoGuard (NGS DNA assay) and EsoCheck (swallowable balloon capsule for cell collection), both based on patented technology licensed from Case Western Reserve University.

• Products aim to provide accurate, patient-friendly alternatives to invasive endoscopy for early detection of Barrett's Esophagus (BE) and esophageal adenocarcinoma (EAC).

• Recent clinical studies and guideline updates support the use of EsoGuard/EsoCheck as non-endoscopic screening tools.

Financial performance and metrics

• Closed $21.975 million private placement of Senior Secured Convertible Notes in November 2024.

• April 2025 public offering raised $16.1 million net; March 2025 offering raised $14.9 million net, both for working capital and general corporate purposes.

• Has incurred operating losses since inception and may not achieve profitability; substantial doubt exists about ability to continue as a going concern.

Use of proceeds and capital allocation

• Proceeds from the 2024 Convertible Notes were used in part to repay a prior convertible note; remaining net proceeds ($18.3 million) for general corporate purposes.

• Recent equity offerings' proceeds allocated to working capital and general corporate purposes.